Surescripts Tackles Prescription Abandonment with Point-of-Care Information That Supports Patient-Provider Shared Decision Making

September 07, 2018

Surescripts was recently recognized with Frost & Sullivan’s Best Practices Award for New Product Innovation. Below is a blog post from guest contributor Nancy Fabozzi, Principal Analyst for Digital Health with Frost & Sullivan.

Surescripts delivers a suite of connected health information solutions designed to streamline electronic prescribing processes. Surescripts has long demonstrated market-leading innovation with its pioneering health information network, the Surescripts Network Alliance. The Surescripts network, which includes the nation’s top electronic health records (EHR) vendors, pharmacy benefit managers, pharmacies, clinicians, health plans, and others, allows participants to securely exchange patient-specific benefit, medication, and prescription information.


The company’s newest offering is its Real-Time Prescription Benefit solution, integrated with its Electronic Prior Authorization solution, which have earned Frost & Sullivan’s New Product Innovation Award for 2018.This award recognizes companies that have successfully introduced new and innovative products that demonstrate exceptional product quality and customer value. Surescripts’ new solutions deliver critical information on a patient’s health plan benefits as well as information about drug pricing, all seamlessly integrated into the provider’s EHR and electronic prescribing workflow. This information allows prescribers to not only quickly and efficiently understand what medications are approved by the patient’s health plan, but also enables them to view pricing information and drug and channel alternatives so that they can engage in an honest discussion with patients about what makes sense from a therapeutic and cost standpoint.

By delivering prescription price transparency at the point of care, Surescripts is helping combat the problem of prescription abandonment, which is largely driven by patients’ financial concerns. It is no surprise this is happening; the rising cost of prescription drugs is a critical and growing concern for the US healthcare system.  According to the IMS Institute for Healthcare Informatics, Americans spent $425 billion on prescriptions in 2015—more than a 12% increase from 2014. Prescription drug cost inflation coincides with the rise of enrollment in high-deductible health plans, which increased 20% from 2008 to 2016. As a result, many people face substantial out-of-pocket costs due to higher co-pays and deductibles. The high cost of drugs means that patients can face unanticipated high costs when they arrive at the pharmacy counter—and many simply walk away without filling their prescription. According to a Truven Health Analytics-NPR Health Poll, 10% of patients who abandon their medication do so because of cost.

Prescription abandonment and medication non-adherence puts patients at risk for developing serious and expensive complications down the road. That is not only bad for patients, but it is also bad for providers who may be negatively impacted, especially if they are in value-based contracts. Everyone loses when patients cannot afford to fill their prescriptions. That is why healthcare providers are turning to new technology solutions that help patients get the medications they need, when they need it, and at a price they are willing to pay.

Surescripts Real-Time Prescription Benefit and expanded Electronic Prior Authorization solutions are designed to address two of the most important root causes of medication non-adherence—complex prior authorizations and a lack of price transparency. Prescribers need complete, correct, and quick information about a patient’s health plan drug coverage to prevent unnecessary delays in issuing a prescription. Once a drug is approved and prescribed, patients also need to be informed about potential out-of-pocket costs so they are prepared to either meet those costs or request an appropriate, more affordable alternative.

Alongside its Real-Time Prescription Benefit and Electronic Prior Authorization offerings, Surescripts is revolutionizing the industry by allowing providers and patients alike to select medication that is both effective and affordable at the point of care. And, unlike its competitors, Surescripts develops its solutions in collaboration with the National Council for Prescription Drug Programs by creating a standards-based platform.

Patient-centric, high-quality healthcare requires real-time patient-specific benefit and price information. Frost & Sullivan independent analysis confirms that Surescripts’ end-to-end workflow management capabilities lead to higher medication adherence, reduced time delays, and greater satisfaction for patients, physicians, and pharmacists.

This blog was first published by Frost & Sullivan. Visit Intelligence in Action to learn more about what Surescripts is doing to deliver prescription price transparency at the point of care.

About the Author
Nancy Fabozzi

Nancy Fabozzi, Principal Analyst for Digital Health, is an 8-year veteran of Frost & Sullivan. Nancy works with Frost & Sullivan’s Transformation Health practice where she tracks a variety of US health IT markets including Electronic Health Records, Revenue Cycle Management, Population Health Management.

Related Articles

June 19, 2019

Health Plans and PBMs Team Up to Get Patients Needed Medications Easier and Faster

Anyone who works in health IT knows how gratifying it is when we offer clinicians a tool that is so much better than old processes, and they run with it. And it’s especially transformative when technology replaces a manual process—one that absorbed a great deal of time and resources.  Read more...
May 21, 2019

An Urgent Call for Transformation: Prescribers Need Better Information and a Streamlined Specialty Prescribing Process

Most likely, you or someone you love has been impacted by a complex or chronic illness like cancer or multiple sclerosis. Sadly, these diseases—and the cost of medications to treat them—are on the rise. More than half of specialty drugs cost in excess of $100,000 a year. As a result, spending on branded specialty medications is rising by 10 percent a year and is projected to surpass half of all medication spending by 2022, even though these drugs comprise just a fraction of all prescribed medications.

May 20, 2019

Federal Government Issues Final Rule: Part D Plans Must Adopt a Real Time Benefit Tool

On May 16, the Centers for Medicare and Medicaid Services (CMS) issued its final rule: Medicare Advantage and Part D Drug Pricing Final Rule (CMS-4180-F).

We’ve been closely following this proposal as it relates to e-prescribing and the Part D prescription drug plan in particular. The rule is designed to accelerate the use of Real Time Benefit Tools (RTBTs), such as Surescripts Real-Time Prescription Benefit.